Table III. The relative risk of a poor response to 1L-CT, according to patient and tumor characteristics.

1L-CT, First-line chemotherapy; ER, estrogen receptor; A/T, anthracycline or taxane chemotherapy; ET, endocrine therapy; TFI, treatment-free interval; DFI, disease-free interval.